Patents Represented by Attorney Melvyn M. Kassenoff
  • Patent number: 6440990
    Abstract: Novel derivatives of rapamycin, particularly 9-deoxo-rapamycins, 26-dihydro-rapamycins, and 40-O-substituted and 28,40-O,O-disubstituted rapamycins. are found to have pharmaceutical utility, particularly as immunosuppressants.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: August 27, 2002
    Assignee: Novartis AG
    Inventors: Sylvain Cottens, Richard Sedrani
  • Patent number: 6383479
    Abstract: Biologically active, pure neutrophil-activating factor (NAF) isolated from human monocytes or after expression of a synthetic NAF gene in E.coli and having the following amino acid sequence Ser-Ala-Lys-Glu-Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His-Pro-Lys-Phe-Ile-Lys-Glu-Leu-Arg-Val-Ile-Glu-Ser-Gly-Pro-His-Cys-Ala-Asn-Thr-Glu-Ile-Ile-Val-Lys-Leu-Ser-Asp-Gly-Arg-Glu-Leu-Cys-Leu-Asp-Pro-Lys-Glu-Asn-Trp-Val-Gln-Arg-Val-Val-Glu-Lys-Phe-Leu-Lys-ArgAla-Glu-Asn-Ser.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 7, 2002
    Assignees: Novartis AG, Theodor Kocher Institut
    Inventors: Heinrich Aschauer, Ivan James Daldon Lindley, Paola Peveri, Alfred Walz
  • Patent number: 6262244
    Abstract: Proteins expressed in NK and some T cells and being transmembrane molecules with Type II membrane protein structure, the extracellular part of the receptor being characterized by a C-type animal lectin domain, DNA sequences encoding such proteins and antibodies against the extracellular part of the transmembrane protein which can activate NK and T cells.
    Type: Grant
    Filed: October 13, 1995
    Date of Patent: July 17, 2001
    Assignees: Regents of the University of Minnesota, Novartis AG
    Inventors: Jeffrey P. Houchins, Toshio Yabe, Cynthia M. McSherry, Fritz H. Bach, Erhard Hofer
  • Patent number: 5955468
    Abstract: Compounds of formula I ##STR1## wherein A, B, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, are useful for the treatment of conditions where prevention or delay of progressive atrophy of the optic nerve is desirable.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 21, 1999
    Assignee: Sandoz Ltd.
    Inventor: Rudolf Markstein
  • Patent number: 5874456
    Abstract: Wood preserving composition comprising a compound of formula I ##STR1## wherein A is selected from ##STR2## whereby the .beta.-carbon attaches to benzene ring of formula (I); R.sub.1 and R.sub.2 are independently H or Cl;R.sub.3 and R.sub.4 are independently R or CH.sub.3 ; andR.sub.5 is methyl, ethyl or cyclopropyland method for preserving wood with the aid of a compound of formula (I).
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: February 23, 1999
    Assignee: Novartis AG
    Inventor: Mark Daniel McDade
  • Patent number: 5840885
    Abstract: A new process is described for the production of 6-alpha-amino-penicillins and 7-alpha-amino-desacetoxy-cephalosporins free from halogen-containing solvents by acylating 6-APA, 7-ADCA or a derivative thereof in a halogen-free solvent.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 24, 1998
    Assignee: Biochemie Gesellschaft m.b.H.
    Inventors: Jose Diago, Johannes Ludescher
  • Patent number: 5827706
    Abstract: The nucleotide sequence which codes for cyclosporin synthetase and similar enzymes and recombinant vectors containing the sequence. The vectors are used in methods for the production of cyclosporin and cyclosporin derivatives.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 27, 1998
    Assignee: Novartis AG
    Inventors: Ernst Leitner, Elisabeth Schneider, Kurt Schoergendorfer, Gerhard Weber
  • Patent number: 5759533
    Abstract: Peptides having the amino acid sequence ##STR1## wherein X is H, Asp-Leu-Tyr-, Ser-Asp-Leu-Tyr- or Asp-Ser-Asp-Leu-Tyr-. The peptide wherein X is H is human neutrophil-activating peptide-2 (hNAP-2) and those wherein X is other than H are natural variants thereof. The peptides have neutrophil-stimulating activity, are structurally related to NAF/NAP-1, .beta.-thromboglobulin, PBP and CTAP-III and may be isolated from leukocytes and platelets and synthesized by standard peptide synthesis processes and recombinant DNA techniques.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 2, 1998
    Assignees: Novartis AG, Theodor Kocher Institut
    Inventors: Marco Baggiolini, Kenneth John Clemetson, Alfred Walz
  • Patent number: 5747054
    Abstract: Plaster formulations of agricultural and pest control chemicals which form slow release briquets in situ.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: May 5, 1998
    Inventors: Kim W. Yang, George J. Junginger, Raymond G. Mockridge, Robert C. Pearce, III
  • Patent number: 5731422
    Abstract: Complexes of formulae I and II ##STR1## wherein the variables are as defined in the specification are useful as dyes for, for example, the mass dyeing of plastics and for lacquers.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 24, 1998
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Bansi Lal Kaul, Dominique Pflieger
  • Patent number: 5719276
    Abstract: A new process is described for the production of 6-alpha-amino-penicillins and 7-alpha-amino-desacetoxy-cephalosporins free from halogen-containing solvents by acylating 6-APA, 7-ADCA or a derivative thereof in a halogen-free solvent.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 17, 1998
    Assignee: Biochemie Gesellschaft m.b.H.
    Inventors: Jose Diago, Johannes Ludescher
  • Patent number: 5719123
    Abstract: Pulmonary administration of Ciclosporin in orthorhombic crystal form (designated "CY-A/X-III"), e.g. for the treatment of obstructive or inflammatory airways disease, e.g. asthma, as well as crystalline Ciclosporin, e.g. CY-A/X-III, in spheroidal particulate form, processes for its preparation and its pharmaceutical use, e.g. for pulmonary administration. Pharmaceutical compositions comprising CY-A/X-III and crystalline Ciclosporin, e.g. CY-A/X-III, in spheroidal particulate form as well as Ciclosporin in solution in aerosol propellants are also provided.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: February 17, 1998
    Assignee: Sandoz Ltd.
    Inventors: John Morley, Andreas Rummelt, Martin List
  • Patent number: 5686410
    Abstract: A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one chelating group linked to an amino group of said peptide, the chelating group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.
    Type: Grant
    Filed: July 18, 1994
    Date of Patent: November 11, 1997
    Assignee: Novartis AG
    Inventors: Rainer Albert, Wilfried Bauer, Janos Pless
  • Patent number: 5679800
    Abstract: Compounds of the formula ##STR1## wherein R, R.sub.1 and R.sub.2 are as defined in the specification and R.sub.3 is amino or --N.dbd.N--K, wherein K is a coupling component radical. The compounds wherein R.sub.3 is --N.dbd.N--K are useful as disperse dyes, and those wherein it is amino are useful as intermediates in the synthesis of those wherein it is --N.dbd.N--K.
    Type: Grant
    Filed: July 15, 1992
    Date of Patent: October 21, 1997
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Robert Egli, Beat Henzi
  • Patent number: 5674532
    Abstract: A process for the production of a dry pancreatin preparation is characterized in that the still moist pancreatin mass, which is obtained after extraction with a solvent or solvent mixture, is treated, before the solvents are finally removed, for a short time in a vacuum cutter, until the mass has been divided and shaped into small spherical particles, and then is finally dried.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 7, 1997
    Assignee: Biochemie Gesellschaft m.b.H.
    Inventors: Gunther Atzl, Franz Langer, Herbert Polleres
  • Patent number: 5668259
    Abstract: Compounds of the formula ##STR1## iron complexes thereof and mixtures of such iron complexes, wherein D is a monocyclic or bicyclic aromatic diazo component radical of the benzene series containing one --SO.sub.3 M group or is ##STR2## R.sub.1 is hydrogen, methyl or ethyl, and R.sub.4 is hydrogen, chloro or C.sub.1-2 alkyl,wherein R' is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl, methoxy(C.sub.2-4 alkyl) or ##STR3## R" is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl or methoxy(C.sub.2-4 alkyl), or--NR'R" is a saturated 5- or 6-membered ring,R.sub.5 is hydrogen, chloro or C.sub.1-2 alkyl, andX is hydrogen or hydroxy,wherein each R.sub.2 is independently hydrogen, chloro, hydroxy, C.sub.1-2 alkyl, C.sub.1-2 alkoxy or --SO.sub.2 NR.sub.o R.sub.o, andeach R.sub.3 is independently hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, --COOM, trifluoromethyl or --NR"'R"",wherein each R"' and R"" is independently C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl, methoxy(C.sub.2-4 alkyl) or carbamoyl(C.sub.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: September 16, 1997
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Jordi Berenuger Barra, Herbert Holliger, Jose Rocas Sorolla
  • Patent number: 5665727
    Abstract: The compounds of formula I, ##STR1## have been found to have excellent topical activity. They are thus indicated for use in the topical treatment of inflammatory and hyperpoliferative skin diseases and of cutaneous manifestations of immunologically-induced illnesses, such as psoriasis.
    Type: Grant
    Filed: August 15, 1994
    Date of Patent: September 9, 1997
    Assignee: Sandoz Ltd.
    Inventors: Maximilian Grassberger, Josef Gottfried Meingassner, Anton Stutz, Peter Stutz
  • Patent number: 5665772
    Abstract: Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: September 9, 1997
    Assignee: Sandoz Ltd.
    Inventors: Sylvain Cottens, Richard Sedrani
  • Patent number: 5659030
    Abstract: A p-toluenesulphonic acid salt of 7-[2-(2-aminothiazol-4-yl)-2-(Z)-hydroximino-acetamido]-3-N,N-dimethylcarb amoyloxymethyl-3-cephem-4-carboxylic acid (isopropoxycarbonyloxy)ethylester, e.g. of formula ##STR1## its use in the production of other salts and a pharmaceutical composition containing it.
    Type: Grant
    Filed: June 14, 1995
    Date of Patent: August 19, 1997
    Assignee: Biochemie Gesellschaft m.b.H.
    Inventors: Johannes Ludescher, Rainer Pucher, Siegfried Wolf
  • Patent number: 5656721
    Abstract: The present invention provides a sugar derivative of a biologically active peptide, which derivative has a prolonged duration of action when compared to the non-sugar modified peptide, and contains at least on one of the amino acid units a sugar residue which is attached to an amino group thereof by a coupling other than a direct N-glycosidic bond, and additionally, when it is a condensation product of a carboxyl group containing sugar and a peptide with less than 8 amino acid units, by a coupling other than a direct amide bond.
    Type: Grant
    Filed: July 7, 1994
    Date of Patent: August 12, 1997
    Assignee: Sandoz Ltd.
    Inventors: Rainer Albert, Wilfried Bauer, Francois Cardinaux, Monika Mergler, Janos Pless, Walter Prikoszovich